Michigan Medicine: First-of-its-kind Treatment for Mastocytosis
August 25, 2026
August 25, 2026
ANN ARBOR, Michigan, Aug. 25 (TNSjou) -- Michigan Medicine, the academic medical center of the University of Michigan, issued the following news release:
* * *
A first-of-its-kind treatment for mastocytosis
For patients with indolent systemic mastocytosis, avapritinib achieved long term disease control
-
Seeking to understand the long term impact and safety of the drug avapritinib on treating patients with indolent systemic mastocy . . .
* * *
A first-of-its-kind treatment for mastocytosis
For patients with indolent systemic mastocytosis, avapritinib achieved long term disease control
-
Seeking to understand the long term impact and safety of the drug avapritinib on treating patients with indolent systemic mastocy . . .